ECCO₂R in Mild-to-Moderate ARDS: What a New Study Using PrismaLung+ Suggests

Acute Care • Healthcare Insight
Doctor checking patient information on screen in hospital

Extracorporeal carbon dioxide removal (ECCO₂R) has long been viewed through the lens of extracorporeal membrane oxygenation (ECMO)—but it’s a distinct therapy with a different objective: CO₂ clearance to support lung-protective ventilation.

In a new clinical study in 58 mechanically ventilated patients¹ with mild-to-moderate acute respiratory distress syndrome (ARDS), investigators evaluated whether ECCO₂R could safely enable reductions in ventilation intensity while maintaining stable CO₂ and pH. Vantive's PrismaLung+ device, a single-use, extracorporeal carbon dioxide removal (ECCO₂R) product, was used in this study. 

In this interview, Dr. Kai Harenski, co-author of the study and Vantive’s global medical lead for Acute Therapies, explains what the data suggest and why technology design—including pump type and low-flow performance—may matter for the next generation of ECCO₂R research.

Key takeaways for clinicians

  • ECCO₂R may help enable gentler ventilation while maintaining physiologic CO₂ and pH
  • Ventilation intensity decreased across parameters including tidal volume, driving pressure, and mechanical power
  • No device or procedure-related serious adverse events were reported in the study population
  • Larger trials are needed to determine whether physiologic benefits translate to clinical outcomes

​

For safe and proper use of the products mentioned herein, please refer to the Operator's Manual or Instructions for Use.

Références

  1. Combes A, et. al. Crit care. 2026; 30(1):15